IMRICOR AND PHILIPS LAUNCH COMMERCIAL IMR LAB SOLUTION

Global collaboration advances MR-guided cardiac interventions toward broader clinical adoption

Key Highlights

- **Commercial launch with Philips**: Imricor and Philips have launched a combined iMR lab solution for advanced MR-guided cardiac interventions
- **Integrated, purpose-built solution**: The offering combines Philips' 1.5T BlueSeal helium-free MR platform with Imricor's NorthStar®, Advantage-MR® and other capital systems along with Imricor's portfolio of single-use catheters and interventional tools
- **Supports adoption of iMR-guided cardiac care**: The initial solution is designed for cardiac interventions, including cardiac electrophysiology procedures, enabling MR-based visualisation and guidance in a purpose-built interventional environment
- **Scalable commercial platform**: The solution provides a foundation for expansion into additional iMR-guided procedures, subject to clinical, regulatory and commercial development
- **Broader route to market**: The collaboration positions Imricor's technology within a combined solution alongside one of the world's leading providers of MR imaging systems
- **Immediate availability in CE-marked markets**: The initial configuration is commercially available now in CE-marked markets, with selected U.S. configurations currently available and further U.S. configurations anticipated subject to regulatory clearances

28 August 2026 – Melbourne, Australia (**27 August 2026** – Minneapolis, MN United States) – **Imricor Medical Systems, Inc.** (**Company** or **Imricor**) (**ASX: IMR**) is pleased to announce the launch of a new Interventional MR (**iMR**) lab solution in collaboration with Royal Philips (NYSE: PHG, AEX: PHIA) (**Philips**). The two companies issued a joint press release today (https://tinyurl.com/yaa89hxf).

The combined iMR lab solution brings together Philips' high-performance 1.5 Tesla (1.5T) MRI platform and interventional workflow capabilities with Imricor's portfolio of MR-compatible systems and consumables. The first commercially available configuration is designed to enable iMR-guided workflows for cardiac interventions, including cardiac electrophysiology procedures.

> *"With interventional MR, the idea is not to move procedures into diagnostic MRI suites, but rather to bring MR imaging into the procedure room. Our collaboration with Philips has always been driven by this shared vision, and with our combined iMR lab solution, that vision becomes a reality today.*
>
> *"Pairing Philips' world-class 1.5T MR platform with Imricor's exclusive portfolio of advanced iMR systems and interventional tools creates the world's first state-of-the-art high-performance iMR lab solution. We believe the future is about advanced image guidance for therapies and interventions, and the future is here now."*
>
> **Steve Wedan — Chair, President and CEO, Imricor**

The solution will be showcased at ESC Congress 2026 in Munich this weekend and is commercially available immediately in CE-marked markets. Certain configurations are also commercially available in the United States. Additional configurations are expected to become available in the United States and other geographies, subject to applicable regulatory clearances.

A longstanding partnership

The launch follows the Philips Third Party Declaration of Compatibility that Imricor announced earlier this month, and it represents a significant milestone in the longstanding Philips-Imricor partnership, advancing since 2012 from joint technology development to the commercial launch of a purpose-built iMR lab solution.

> *"Our ambition is not only to advance what clinicians can see with MRI, but also what they can do with it,"*
>
> *"Philips has a long history of helping clinicians perform image-guided procedures with confidence, and we believe MRI can play an even greater role in providing care. With this new iMR lab solution, enabled through our collaboration with Imricor, we're expanding the role of cardiac MRI from diagnosis into the treatment environment.*
>
> *"Cardiac electrophysiology is just the beginning. This iMR lab solution represents an important step in Philips' strategy to advance MRI across the care continuum, creating a platform that can expand into additional clinical areas while helping clinicians deliver the best possible care for their patients."*
>
> **Ioannis Panagiotelis, PhD — Business Leader, Magnetic Resonance, Philips**

ENDS

Authorised for release by Steve Wedan, Executive Chair, President, and CEO

Media and Investor Relations Contacts:

Simon Hinsley
Executive Director, NWR
simon@nwrcommunications.com.au
+61 401 909 653

Nick Corkill
VP Corporate Strategy, Imricor
nick.corkill@imricor.com
+61 450 475 633

About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is striving to make interventional medical procedures better, safer, and more cost effective by making it possible for these procedures to be performed under real-time magnetic resonance (MR) guidance, rather than under x-ray fluoroscopy guidance, thus taking advantage of MR's superior imaging capabilities.

Imricor's Products

Imricor is a pioneer and world leader in developing MR-compatible products for interventional MR (iMR) procedures. The Company's products include capital equipment, such as the NorthStar® Mapping System and the Advantage-MR® EP Recorder/Stimulator. Single-use devices include a variety of ablation catheters, diagnostic catheters, steerable sheaths, and other tools used in an iMR lab.

Imricor's products are approved in the European Union, the Kingdom of Saudi Arabia, and New Zealand. NorthStar and Vision-MR Diagnostic Catheter are cleared in the US.

Foreign Ownership Restrictions

Imricor's CHESS Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons excluding qualified institutional buyers (QIBs, as defined in Rule 144A under the Securities Act). However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.